KRAS and adenocarcinoma in situ: This is difficult to reconcile with the observation that atypical adenomatous hyperplasia (AAH), the presumed dysplastic precursor of adenocarcinoma, has a higher incidence of KRAS mutation than adenocarcinoma-in-situ and much higher than invasive adenocarcinoma [23].